SpePharm gets €16mm in private round
Executive Summary
SpePharm Holdings BV (cancer and critical care therapeutics) raised €16mm ($23.6mm) through a private financing from TVM Capital, Signet Healthcare Partners, Paul Capital Healthcare, and members of the company's senior management team. SpePharm concurrently announced a €10mm revenue interest acquisition financing agreement signed with Paul Capital to fund the recent purchase of European rights to Dantrium for hyperthermia from Procter & Gamble.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice